Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT07280819
Starting soon Not applicable

Nutritional and Physical Intervention During Bed Rest

NCT07280819 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2026-01
Last updated
2025-12-12

Condition(s) studied

Muscle Protein Synthetic Response to Protein

Investigational drug(s) / intervention(s)

Nutritionally complete tube feed providing a sole source of nutrition with a plant-dominant protein mixNutritionally complete tube feed providing a sole source of nutrition with an animal-based protein mixNeuromuscular Electrical Stimulation (NMES)

Nutritionally complete tube feed providing a sole source of nutrition with a plant-dominant protein mix: Containing plant-based proteins.

Nutritionally complete tube feed providing a sole source of nutrition with an animal-based protein mix: Containing animal-based proteins.

Neuromuscular Electrical Stimulation (NMES): The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min).

Study summary

Hospitalization often involves long periods of bed rest and reduced nutritional intake, which can lead to skeletal muscle loss and anabolic resistance. These effects slow recovery and increase the risk of complications, long-term disability and healthcare costs. Animal-based proteins are effective at stimulating muscle protein synthesis (MPS) because they contain all essential amino acids and have high bioavailability, but they are less sustainable. Plant-based proteins are more environmentally friendly but may be less effective for MPS due to lower essential amino acid content and lower digestibility. Combining different plant proteins may improve their quality, yet their impact during bed rest is still unclear. Neuromuscular electrical stimulation (NMES) may help counteract anabolic resistance by mimicking exercise, but its long-term effects in bedridden individuals are not well studied.

This prospective, randomized, controlled trial aims to assess the effects of a nutritional intervention (plant-dominant versus dairy-based protein) and a physical stimulus (NMES versus non-NMES) on MPS during 4 days of bed rest in healthy young adults.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy (assessed based on routine medical questionnaire) * Male and female sexes * Aged between 18 and 35 years inclusive * BMI between 18.5 and 30.0 kg/m² Exclusion Criteria: * Vegan diet * Allergies or intolerance to cow's milk products, fish, soy, and/or pea protein * Galactosemia * Smoking on a weekly basis (i.e., every week) * Diagnosed diabetes mellitus * Chronic corticosteroid use * Severe kidney and/or liver failure * Dialysis * Bleeding disorders, including anticoagulant and antiplatelet therapy * Currently pregnant

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maastricht University Maastricht Netherlands

More Maastricht University Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07280819 on ClinicalTrials.gov ↗ ← All trials in the Netherlands